TP53 and acute myeloid leukemia: Some studies showed that the survival rate among AML patients with unfavorable-risk cytogenetic profiles, TP53 mutations, or both and are treated with DAC is comparable to that of patients who have an intermediate-risk cytogenetic profile and receive DAC.